Description: Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Our non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Our portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
Home Page: www.gelesis.com
GLS Technical Analysis
501 Boylston Street
Boston,
MA
02116
United States
Phone:
617 456 4718
Officers
| Name | Title |
|---|---|
| Mr. Yishai Zohar | Founder, Pres, CEO & Director |
| Mr. Elliot Maltz CPA | CFO & Treasurer |
| Dr. David Pass Pharm.D. | COO & Chief Commercial Officer |
| Dr. Elaine Chiquette Pharm.D. | Chief Scientific Officer |
| Ms. Joy Bauer M.S., MS, RDN | Chief Nutrition Officer of Plenity |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.2308 |
| Price-to-Sales TTM: | 0.6262 |
| IPO Date: | 2022-01-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 101 |